Andersen Tawil Syndrome Treatment Market Expected to Achieve a CAGR of 8.26 % Towards US$ 4.2 Billion by 2033 | FMI

North America leads in Andersen disease treatment, driven by key players, advanced options, robust healthcare, rising prevalence & heightened health awareness.

FMI Logo

NEWARK, DELAWARE, UNITED STATES OF AMERICA, November 29, 2023 /EINPresswire.com/ -- The global Andersen Tawil syndrome treatment market is expected to surpass an impressive valuation of US$ 1.9 Billion in 2023 and is projected to reach US$ 4.2 Billion by 2033, with a CAGR of 8.26%. Rising government assistance, provision of incentives to pharmaceutical companies, increasing awareness among people and social groups, the physician to physician communication to find effective treatment methods to treat rare diseases, increase in facilities for patients, rise in the incentives for research due to the prevalence of non-profit organizations that promote health to treat rare diseases will contribute to the expansion of the market.

Request a Sample of this Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16357

Easy international access to data on the Andersen-Tawil syndrome in recent years is supporting associated research efforts which aids in market expansion. Also, growing government investments and incentives towards rare disease research are supporting in creating drug demand for Andersen Tawil syndrome. Moreover, the growing involvement of private and public organizations supporting treatment and raising awareness will positively influence future developments. However, the low prevalence of the Andersen-Tawil syndrome and the dearth of awareness remains key problem hurting market players. The high risk of misdiagnosis and undiagnosed cases continue as key issues that restrain the industry’s growth. Further, High costs associated with rare disease research will hold back innovations and growth prospects which will hinder growth.

There are few other factors that hold back the growth of the global market, such as the challenges in research and development, delay in diagnosis thereby delaying the treatment, limitations with respect to expertise, and characteristic dearth of attractiveness from an economic standpoint, which eventually has resulted in the lack of commercial interest for private investors, lack of regulatory framework in developing economies coupled with lack of skilled healthcare personnel.

Key Takeaways:

- Increasing focus of the government to prioritize drugs for the treatment of rare diseases is expected to propel growth

- Increasing participation of organizations to support the treatment and to create awareness is also anticipated to drive the growth of the market.

- Growth in R&D investments by the key players in the Andersen-Tawil Syndrome Market is also expected to aid in market expansion.

- North America is expected to dominate the market of Andersen Tawil syndrome.

- South Asia is projected to witness the fastest growth during the forecast period.

- Type 1 Andersen Tawil Syndrome is projected to dominate the market with a 59% market share by 2033.

“Increased government funding efforts aimed towards improving diagnostic procedures are anticipated to generate lucrative prospects for the participants in the Andersen-Tawil syndrome market. Non-profit organizations are playing key roles in raising awareness and positively influencing market developments”, - Says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Leading Key Players:

- Teva Pharmaceuticals Ltd,

- Zydus Pharmaceuticals, Inc.,

- Sun Pharmaceuticals Industries Ltd.,

- Advanz Pharmaceuticals,

- Novartis AG,

- Mylan N.V,

- Aurobindo Pharma,

- Dr. Reddy’s Laboratories Ltd.,

· Viatris Inc.,

· Pfizer Inc.

Some recent developments in this market are:

· In April 2021, Teva Pharmaceuticals was acquired by Karo Pharma Aktiebolag with the aim of gaining the European OTC brand portfolios and drug research including rare disease solutions. Also, Sun Pharmaceutical Industries Ltd. announced the acquisition of 66% ownership interest in Trikaal Mediinfotech, and AWACS, through its subsidiary ABCD Technologies LLP.

· In December 2016, Strongbridge Biopharma plc acquired U.S. commercialization rights for Keveyis from Taro Pharmaceutical Industries Ltd (a subsidiary of Sun Pharmaceutical Industries Ltd) for the treatment of periodic paralysis. Under the terms of the agreement, Taro Pharmaceutical Industries Ltd to receive an upfront payment of USD 8.50 mm and is also eligible to receive additional future payments upon the achievement of certain sales unit milestones. The acquisition of U.S. rights expands the company's rare disease portfolio to include neuromuscular diseases.

More Valuable Insights:

Future Market Insights, in its new offering, presents an unbiased analysis of the Andersen Tawil Syndrome Treatment Market, presenting a historical analysis from 2017 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights on the basis of Disease type (Type 1, Type 2) By Drug class (Carbonic Anhydrate Inhibitors, Acetazolamide, Dichlorpenamide, Antiarrhythmic Drugs, Amiodarone, Flecainide, Beta-Blockers, Atenolol) By Distribution channel (Hospital Pharmacies, Retail pharmacies, Online Pharmacies) and by region (North America, Latin America, Europe, South Asia, East Asia, Oceania MEA)

Key Segments:

By Disease Type:

Type 1
Type 2

By Drug Class:

Carbonic Anhydrate Inhibitors
Acetazolamide
Dichloropenamide
Antiarrhythmic Drugs
Amiodarone
Flecainide
Beta-Blockers
Atenolol

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Authored By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Explore FMI's Extensive Coverage in Healthcare Domain:

Bone Grafts and Substitutes Market was valued at around US$ 3 Billion in 2021. With a projected CAGR of 7.1% for the next ten years, the market is likely to reach a valuation of nearly US$ 6.3 Billion by the end of 2032.

Coronary Stents Market is expected to grow at a significant CAGR between 2022 and 2032, in comparison to the 7% CAGR registered from 2016 to 2021.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Ankush Nikam
Future Market Insights, Inc.
+91 90966 84197
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
YouTube
